Stock Market & Financial Investment News

News Breaks March 21, 2013 08:17 EDT ISIS, BIIB Isis Pharmaceuticals data compelling, says BMO Capital BMO Capital believes that data from a Phase I test of Isis' (ISIS) and Biogen's (BIIB) ISIS-SMN-Rx, an antisense oligonucleotide, for children with spinal muscular atrophy, suggests that the drug has a substantial clinical benefit. The firm raised its price target on Isis to $22 from $17 and maintains an Outperform rating. News For ISIS;BIIB From The Last 14 Days Check below for free stories on ISIS;BIIB the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 17, 2013 08:54 EDT BIIB Biogen weekly MS drug scripts up 39%, says Citigroup Subscribe for More Information June 12, 2013 16:20 EDT BIIB On The Fly: Closing Wrap Stocks on Wall Street were lower despite opening sharply higher as the market looked to avoid its first three day losing streak of the year. Downside momentum quickly took hold however, and the averages moved steadily lower through the session, moving to their lows in the final hour of trading but finishing just off those levels. ECONOMIC EVENTS: In the U.S., the MBA's purchase applications composite index rose 5.0% for the week. The U.S. posted a $139B May budget deficit against expectations for a $130B deficit, and compared to a $124.6B deficit a year ago. In Europe, factory production in the 17-nation euro area rose 0.4% in April from March, compared to expectations for it to remain unchanged. COMPANY NEWS: Cooper Tire (CTB) agreed to be acquired by India's Apollo Tyres for $35.00 per share in cash, or $2.5B. Cooper shares surged $10.10, or 41.12%, to $34.66 to trade near $34.50 following the deal announcement, while peer Goodyear Tire (GT) advanced about 33c, or 2.26%, to $14.93... Live Nation (LYV) shares gained $2.33, or 16.84%, to $16.17 after the company announced it prevailed in an arbitration ruling related to a ticketing license software agreement... MAJOR MOVERS: Among the notable gainers was Ulta Salon (ULTA), up $12.51, or 14.87%, to $96.64 following its quarterly earnings report. Also higher was Health Management (HMA), up $1.58, or 11.34%, to $15.51 after Glenview Capital said in a filing it is seeking to repeal a provision that prevents entities from holding more than 15% of the company's stock and saying it would look to nominate candidates to the company's board. Among noteworthy losers was Biogen (BIIB), down $16.48, or 7.39%, to $206.55 after the stock was downgraded to Neutral from Buy at Citigroup, which cited concerns that EU medical regulators are unlikely to approve the company's multiple sclerosis treatment. Also lower were U.S.-listed shares of Vodafone (VOD), down 71c, or 2.47%, to $28.12 after the company confirmed it approached Kabel Deutschland about a possible deal. INDICES: The Dow was down 126.79, or 0.84%, to 14,995.23; the S&P 500 was down 13.61, or 0.84%, to 1,612.52; the Nasdaq was down 36.52, or 1.06%, to 3,400.43. 10:31 EDT BIIB Biogen retreats after analyst cuts rating to Neutral Subscribe for More Information 10:14 EDT BIIB On the Fly: Downgrade Summary Subscribe for More Information 07:38 EDT BIIB Biogen price target raised to $268 from $219 at Brean Capital Subscribe for More Information 06:01 EDT BIIB Biogen downgraded to Neutral from Buy at Citigroup Subscribe for More Information June 11, 2013 11:47 EDT BIIB Deutsche Bank's biotech analyst holds an analyst/industry conference call Biotech Analyst Karnauskas discusses Biogen's (BIIB) treatment for Multiple Sclerosis, Tecfidera, as well as reviewing IMS Tecfidera data, on an Analyst/Industry conference call to be held on June 11 at 3 pm. June 10, 2013 07:40 EDT BIIB Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information 07:04 EDT ISIS Xenon licenses antisense drug SEN701 from Isis Pharmaceuticals Subscribe for More Information June 7, 2013 07:13 EDT BIIB Biogen shares should be bought on recent weakness, says RBC Capital Subscribe for More Information June 6, 2013 07:01 EDT ISIS Isis Pharmaceuticals earns $6M payment from AstraZeneca Subscribe for More Information June 5, 2013 14:08 EDT BIIB Deutsche Bank sees upside to Biogen's Quick-Start program Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.